MINI FUTURE LONG - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 09:23:32 2024-06-24 EDT | ||
| 19.55 EUR / 19.75 EUR | 0.00% |
|
| Current month | +7.97% | ||
| 1 month | +16.96% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-24 | 19.53 | -0.61% |
| 24-06-21 | 19.65 | -0.10% |
| 24-06-20 | 19.67 | +2.50% |
| 24-06-19 | 19.19 | -0.93% |
| 24-06-18 | 19.37 | -3.00% |
Delayed Quote Börse Stuttgart
Last update June 24, 2024 at 06:05 am
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MD95MD |
| ISIN | DE000MD95MD3 |
| Date issued | 2022-10-06 |
| Strike | 260.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 7.83 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 20.93 € |
|---|---|
| Lowest since issue | 5.09 € |
| Spread | 0.2 € |
| Spread % | 1.01% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
468.7
USD
Average target price
463.4
USD
Spread / Average Target
-1.13%
- Stock Market
- Certificates
- Certificat
